Alzheimer's Research & Therapy

Submit a manuscript Register

Explore journal

Advertisement

Articles

Supplements

Display/download options Articles per page: 25 | 50 | 100

Display options

Editor's summary Citation

Download options

Send
To

		Review Role of structural MRI in Alzheimer's disease Prashanthi Vemuri, Clifford R Jack Alzheimer's Research & Therapy 2010, 2:23 (31 August 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Structural MRI (sMRI) plays many roles as an Alzheimer’s disease (AD) biomarker and is of both prognostic and diagnostic value, but further work is needed in order to integrate it with other clinical measures.
		Research Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice? Philippe Robert, Steven Ferris, Serge Gauthier, Ralf Ihl, Bengt Winblad, Frank Tennigkeit Alzheimer's Research & Therapy 2010, 2:24 (26 August 2010) Abstract \| Provisional PDF \| PubMed
		Viewpoint The role of animal models in advancing amyloid-beta immunotherapy to the clinic Dora Games, Peter Seubert Alzheimer's Research & Therapy 2010, 2:22 (29 July 2010) Abstract \| Full text \| PDF \| PubMed
		Review The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation? Kerensa Broersen, Frederic Rousseau, Joost Schymkowitz Alzheimer's Research & Therapy 2010, 2:12 (14 July 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Amyloid beta has been identified as neurotoxic in patients with Alzheimer’s disease (AD), but we must take into account its structural characteristics, as well as size, when exploring AD development.
		Commentary Advances in quantitative magnetic resonance imaging-based biomarkers for Alzheimer disease Bradford C Dickerson Alzheimer's Research & Therapy 2010, 2:21 (6 July 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Advances in data acquisition and image-processing algorithms are helping us to measure brain changes in Alzheimer’s disease, but many challenges remain in translating this to the clinic.
		Commentary Mild traumatic brain injury: a risk factor for neurodegeneration Brandon E Gavett, Robert A Stern, Robert C Cantu, Christopher J Nowinski, Ann C McKee Alzheimer's Research & Therapy 2010, 2:18 (25 June 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Head trauma can lead to progressive neurodegeneration and further study of this risk factor could help us improve prevention and treatment strategies for other neurodegenerative diseases.
		Viewpoint Pro: Can biomarkers be gold standards in Alzheimer's disease? Reisa Sperling, Keith Johnson Alzheimer's Research & Therapy 2010, 2:17 (25 June 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Sperling and Johnson argue that biomarkers can approximate the diagnostic accuracy of autopsy in Alzheimer’s patients and may be able to track progression of the disease prior to significant cognitive impairment.
		Viewpoint Con: Can biomarkers be gold standards in Alzheimer's disease? Kenneth Rockwood Alzheimer's Research & Therapy 2010, 2:16 (25 June 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Rockwood argues that we should employ a number of clinical measures, such as neuropsychological tests and clinical interviews, rather than relying solely on biomarkers to predict Alzheimer’s disease outcome.
		Research Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease Erik Stomrud, Maria Bj�rkqvist, Sabina Janciauskiene, Lennart Minthon, Oskar Hansson Alzheimer's Research & Therapy 2010, 2:20 (24 June 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Matrix metalloproteinases are elevated in patients with Alzheimer’s disease (AD) and might be associated with early pathogenesis of AD in individuals who have not developed overt cognitive dysfunction.
		Research *Vascular health, diabetes, APOE* and dementia: the Aging, Demographics, and Memory Study** David J Llewellyn, Iain A Lang, Fiona E Matthews, Brenda L Plassman, Mary AM Rogers, Lewis B Morgenstern, Gwenith G Fisher, Mohammed U Kabeto, Kenneth M Langa Alzheimer's Research & Therapy 2010, 2:19 (24 June 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Stroke and the APOE epsilon4 allele are strongly associated with dementia, and antihypertensive medications may inform the development of more effective interventions and treatments.
		Commentary Should the ApoE genotype be a covariate for clinical trials in Alzheimer disease? Martin R Farlow Alzheimer's Research & Therapy 2010, 2:15 (8 June 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Variations in the ApoE genotype may affect the rate of disease progression and response to therapy in Alzheimer’s disease, suggesting it should be included as a covariate for future trials.
		Commentary The involvement of cell cycle events in the pathogenesis of Alzheimer's disease Karl Herrup Alzheimer's Research & Therapy 2010, 2:13 (20 May 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Cell cycle events in Alzheimer’s disease and other late-onset neurodegenerative diseases are not fully understood, but elucidating these complex relationships may pave the way to developing new therapeutic interventions.
		Correction Correction: Predicting progression of Alzheimer's disease Rachelle S Doody, Valory Pavlik, Paul Massman, Susan Rountree, Eveleen Darby, Wenyaw Chan Alzheimer's Research & Therapy 2010, 2:14 (18 May 2010) Abstract \| Full text \| PDF \| PubMed
		Commentary Increasing incidence of dementia in the oldest old: evidence and implications Bryan D James, Julie A Schneider Alzheimer's Research & Therapy 2010, 2:9 (13 May 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary The implications of a study suggesting an exponential rise in dementia in persons 90 years and older are discussed and compared to other studies reporting a slowing incidence.
		Viewpoint Pro: Can neuropathology really confirm the exact diagnosis? Margaret M Esiri Alzheimer's Research & Therapy 2010, 2:10 (7 May 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Esiri discusses the benefits of neuropathology as a diagnostic tool for Alzheimer’s disease, arguing that it still holds the key to revealing the complex molecular and cellular mechanisms of the disease.
		Viewpoint Con: Can neuropathology really confirm the exact diagnosis? Kurt A Jellinger Alzheimer's Research & Therapy 2010, 2:11 (7 May 2010) Abstract \| Full text \| PDF \| PubMed \| 1 comment \| Editor’s summary Jellinger comments on the drawbacks of neuropathology as a diagnostic tool for Alzheimer’s disease and argues that to improve the accuracy and reproducibility of its diagnosis, we should be using harmonized techniques.
		Commentary Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease? Kaj Blennow, Henrik Zetterberg Alzheimer's Research & Therapy 2010, 2:8 (30 April 2010) Abstract \| Full text \| PDF \| PubMed
		Commentary Inflammation in the Alzheimer's disease cascade: culprit or innocent bystander? Zaldy S Tan, Sudha Seshadri Alzheimer's Research & Therapy 2010, 2:6 (12 April 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Tan and Seshadri consider evidence linking inflammation to Alzheimer’s disease risk, discussing the growing body of evidence that suggests inflammatory biomarkers could be used to risk-stratify people for preventative/therapeutic interventions.
		Commentary Can novel therapeutics halt the amyloid cascade? Niels D Prins, Pieter Visser, Philip Scheltens Alzheimer's Research & Therapy 2010, 2:5 (9 April 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Prins and colleagues discuss the negative results of the recent bapineuzumab and tarenflurbil trials, the lessons learnt from them and comment on the potential implications for future novel therapeutics.
		Commentary Pinpointing key mechanisms in Alzheimer's disease development Julie Williams Alzheimer's Research & Therapy 2010, 2:4 (31 March 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Williams comments on a recent study implicating inflammation and innate immunity in Alzheimer’s disease development, discussing these results in the context of recent genetic studies on the disease.
		Research A novel Aβ isoform pattern in CSF reflects γ-secretase inhibition in Alzheimer disease Erik Portelius, Robert A Dean, Mikael K Gustavsson, Ulf Andreasson, Henrik Zetterberg, Eric Siemers, Kaj Blennow Alzheimer's Research & Therapy 2010, 2:7 (29 March 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Amyloid beta isoforms in cerebrospinal fluid increase during gamma-secretase inhibitor treatment in Alzheimer's disease (AD), and may be used as novel sensitive biomarkers to monitor the biochemical effect in clinical trials.
		Review Genetics of Alzheimer disease in the pre- and post-GWAS era Nil�fer Ertekin-Taner Alzheimer's Research & Therapy 2010, 2:3 (5 March 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Ertekin-Taner summarises genetic studies preceding the genome-wide association study (GWAS) era and discusses insights into genetics of Alzheimer’s following recent GWAS results, which may translate into future therapies.
		Research Predicting progression of Alzheimer's disease Rachelle S Doody, Valory Pavlik, Paul Massman, Susan Rountree, Eveleen Darby, Wenyaw Chan Alzheimer's Research & Therapy 2010, 2:2 (23 February 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Baseline cognitive assessments of probable Alzheimer’s disease patients can help predict future performance in cognition and activities of daily living, and should be considered when designing clinical trials in Alzheimer’s disease.
		Review Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy Elina Zotova, James AR Nicoll, Raj Kalaria, Clive Holmes, Delphine Boche Alzheimer's Research & Therapy 2010, 2:1 (22 January 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Zotova et al. review the immune processes involved in Alzheimer’s disease pathogenesis and highlight the importance of addressing neuro-immune interactions when devising therapeutic strategies.
		Research Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease Susan D Rountree, Wenyaw Chan, Valory N Pavlik, Eveleen J Darby, Samina Siddiqui, Rachelle S Doody Alzheimer's Research & Therapy 2009, 1:7 (21 October 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Persistent treatment with cholinesterase inhibitors and/or memantine had a positive impact on Alzheimers disease (AD) progression by multiple cognitive and functional outcome measures.
		Review Proteinopathy-induced neuronal senescence: a hypothesis for brain failure in Alzheimer's and other neurodegenerative diseases Todd E Golde, Victor M Miller Alzheimer's Research & Therapy 2009, 1:5 (12 October 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Golde and Miller propose an integrative hypothesis that provides new insights into how a variety of misfolded protein aggregates can result in neurodegeneration.
		Review Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease Roy O Weller, Stephen D Preston, Malavika Subash, Roxana O Carare Alzheimer's Research & Therapy 2009, 1:6 (12 October 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Weller et al. highlight the importance of addressing neuro-immune interactions when devising therapeutic strategies for Alzheimer's disease.
		Review Angiotensins and Alzheimer's disease: a bench to bedside overview Patrick G Kehoe Alzheimer's Research & Therapy 2009, 1:3 (9 July 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Kehoe proposes angiotensins and associated enzymatic pathways as important mediators of recognized but undefined links between blood pressure and Alzheimer’s disease.
		Commentary Alzheimer's disease therapeutic research: the path forward Paul S Aisen Alzheimer's Research & Therapy 2009, 1:2 (9 July 2009) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Despite recent negative trial results, a clear path forward is emerging in Alzheimer’s disease therapeutic research using newly available tools to allow the study of new treatments at earlier stages in the disease process.
		Editorial Welcome to Alzheimer's Research & Therapy Ann Donnelly, Doug Galasko, Todd Golde, Frances Mulvany, Gordon Wilcock Alzheimer's Research & Therapy 2009, 1:1 (9 July 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Douglas Galasko, Todd Golde and Gordon Wilcock, Editors-in-chief, introduce Alzheimer’s Research & Therapy, the major forum for translational research into Alzheimer’s disease.
		Review Beyond mild cognitive impairment: vascular cognitive impairment, no dementia (VCIND) Blossom CM Stephan, Fiona E Matthews, Kay-Tee Khaw, Carole Dufouil, Carol Brayne Alzheimer's Research & Therapy 2009, 1:4 (9 July 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Stephan et al. review the concept of ‘vascular cognitive impairment, no dementia’ (VCIND) and its application for screening individuals at increased risk of dementia secondary to vascular disease and its risk factors.

		Review Role of structural MRI in Alzheimer's disease Prashanthi Vemuri, Clifford R Jack Alzheimer's Research & Therapy 2010, 2:23 (31 August 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Structural MRI (sMRI) plays many roles as an Alzheimer’s disease (AD) biomarker and is of both prognostic and diagnostic value, but further work is needed in order to integrate it with other clinical measures.
		Research Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice? Philippe Robert, Steven Ferris, Serge Gauthier, Ralf Ihl, Bengt Winblad, Frank Tennigkeit Alzheimer's Research & Therapy 2010, 2:24 (26 August 2010) Abstract \| Provisional PDF \| PubMed
		Viewpoint The role of animal models in advancing amyloid-beta immunotherapy to the clinic Dora Games, Peter Seubert Alzheimer's Research & Therapy 2010, 2:22 (29 July 2010) Abstract \| Full text \| PDF \| PubMed
		Review The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation? Kerensa Broersen, Frederic Rousseau, Joost Schymkowitz Alzheimer's Research & Therapy 2010, 2:12 (14 July 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Amyloid beta has been identified as neurotoxic in patients with Alzheimer’s disease (AD), but we must take into account its structural characteristics, as well as size, when exploring AD development.
		Commentary Advances in quantitative magnetic resonance imaging-based biomarkers for Alzheimer disease Bradford C Dickerson Alzheimer's Research & Therapy 2010, 2:21 (6 July 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Advances in data acquisition and image-processing algorithms are helping us to measure brain changes in Alzheimer’s disease, but many challenges remain in translating this to the clinic.
		Commentary Mild traumatic brain injury: a risk factor for neurodegeneration Brandon E Gavett, Robert A Stern, Robert C Cantu, Christopher J Nowinski, Ann C McKee Alzheimer's Research & Therapy 2010, 2:18 (25 June 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Head trauma can lead to progressive neurodegeneration and further study of this risk factor could help us improve prevention and treatment strategies for other neurodegenerative diseases.
		Viewpoint Pro: Can biomarkers be gold standards in Alzheimer's disease? Reisa Sperling, Keith Johnson Alzheimer's Research & Therapy 2010, 2:17 (25 June 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Sperling and Johnson argue that biomarkers can approximate the diagnostic accuracy of autopsy in Alzheimer’s patients and may be able to track progression of the disease prior to significant cognitive impairment.
		Viewpoint Con: Can biomarkers be gold standards in Alzheimer's disease? Kenneth Rockwood Alzheimer's Research & Therapy 2010, 2:16 (25 June 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Rockwood argues that we should employ a number of clinical measures, such as neuropsychological tests and clinical interviews, rather than relying solely on biomarkers to predict Alzheimer’s disease outcome.
		Research Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease Erik Stomrud, Maria Bj�rkqvist, Sabina Janciauskiene, Lennart Minthon, Oskar Hansson Alzheimer's Research & Therapy 2010, 2:20 (24 June 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Matrix metalloproteinases are elevated in patients with Alzheimer’s disease (AD) and might be associated with early pathogenesis of AD in individuals who have not developed overt cognitive dysfunction.
		Research *Vascular health, diabetes, APOE* and dementia: the Aging, Demographics, and Memory Study** David J Llewellyn, Iain A Lang, Fiona E Matthews, Brenda L Plassman, Mary AM Rogers, Lewis B Morgenstern, Gwenith G Fisher, Mohammed U Kabeto, Kenneth M Langa Alzheimer's Research & Therapy 2010, 2:19 (24 June 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Stroke and the APOE epsilon4 allele are strongly associated with dementia, and antihypertensive medications may inform the development of more effective interventions and treatments.
		Commentary Should the ApoE genotype be a covariate for clinical trials in Alzheimer disease? Martin R Farlow Alzheimer's Research & Therapy 2010, 2:15 (8 June 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Variations in the ApoE genotype may affect the rate of disease progression and response to therapy in Alzheimer’s disease, suggesting it should be included as a covariate for future trials.
		Commentary The involvement of cell cycle events in the pathogenesis of Alzheimer's disease Karl Herrup Alzheimer's Research & Therapy 2010, 2:13 (20 May 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Cell cycle events in Alzheimer’s disease and other late-onset neurodegenerative diseases are not fully understood, but elucidating these complex relationships may pave the way to developing new therapeutic interventions.
		Correction Correction: Predicting progression of Alzheimer's disease Rachelle S Doody, Valory Pavlik, Paul Massman, Susan Rountree, Eveleen Darby, Wenyaw Chan Alzheimer's Research & Therapy 2010, 2:14 (18 May 2010) Abstract \| Full text \| PDF \| PubMed
		Commentary Increasing incidence of dementia in the oldest old: evidence and implications Bryan D James, Julie A Schneider Alzheimer's Research & Therapy 2010, 2:9 (13 May 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary The implications of a study suggesting an exponential rise in dementia in persons 90 years and older are discussed and compared to other studies reporting a slowing incidence.
		Viewpoint Pro: Can neuropathology really confirm the exact diagnosis? Margaret M Esiri Alzheimer's Research & Therapy 2010, 2:10 (7 May 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Esiri discusses the benefits of neuropathology as a diagnostic tool for Alzheimer’s disease, arguing that it still holds the key to revealing the complex molecular and cellular mechanisms of the disease.
		Viewpoint Con: Can neuropathology really confirm the exact diagnosis? Kurt A Jellinger Alzheimer's Research & Therapy 2010, 2:11 (7 May 2010) Abstract \| Full text \| PDF \| PubMed \| 1 comment \| Editor’s summary Jellinger comments on the drawbacks of neuropathology as a diagnostic tool for Alzheimer’s disease and argues that to improve the accuracy and reproducibility of its diagnosis, we should be using harmonized techniques.
		Commentary Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease? Kaj Blennow, Henrik Zetterberg Alzheimer's Research & Therapy 2010, 2:8 (30 April 2010) Abstract \| Full text \| PDF \| PubMed
		Commentary Inflammation in the Alzheimer's disease cascade: culprit or innocent bystander? Zaldy S Tan, Sudha Seshadri Alzheimer's Research & Therapy 2010, 2:6 (12 April 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Tan and Seshadri consider evidence linking inflammation to Alzheimer’s disease risk, discussing the growing body of evidence that suggests inflammatory biomarkers could be used to risk-stratify people for preventative/therapeutic interventions.
		Commentary Can novel therapeutics halt the amyloid cascade? Niels D Prins, Pieter Visser, Philip Scheltens Alzheimer's Research & Therapy 2010, 2:5 (9 April 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Prins and colleagues discuss the negative results of the recent bapineuzumab and tarenflurbil trials, the lessons learnt from them and comment on the potential implications for future novel therapeutics.
		Commentary Pinpointing key mechanisms in Alzheimer's disease development Julie Williams Alzheimer's Research & Therapy 2010, 2:4 (31 March 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Williams comments on a recent study implicating inflammation and innate immunity in Alzheimer’s disease development, discussing these results in the context of recent genetic studies on the disease.
		Research A novel Aβ isoform pattern in CSF reflects γ-secretase inhibition in Alzheimer disease Erik Portelius, Robert A Dean, Mikael K Gustavsson, Ulf Andreasson, Henrik Zetterberg, Eric Siemers, Kaj Blennow Alzheimer's Research & Therapy 2010, 2:7 (29 March 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Amyloid beta isoforms in cerebrospinal fluid increase during gamma-secretase inhibitor treatment in Alzheimer's disease (AD), and may be used as novel sensitive biomarkers to monitor the biochemical effect in clinical trials.
		Review Genetics of Alzheimer disease in the pre- and post-GWAS era Nil�fer Ertekin-Taner Alzheimer's Research & Therapy 2010, 2:3 (5 March 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Ertekin-Taner summarises genetic studies preceding the genome-wide association study (GWAS) era and discusses insights into genetics of Alzheimer’s following recent GWAS results, which may translate into future therapies.
		Research Predicting progression of Alzheimer's disease Rachelle S Doody, Valory Pavlik, Paul Massman, Susan Rountree, Eveleen Darby, Wenyaw Chan Alzheimer's Research & Therapy 2010, 2:2 (23 February 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Baseline cognitive assessments of probable Alzheimer’s disease patients can help predict future performance in cognition and activities of daily living, and should be considered when designing clinical trials in Alzheimer’s disease.
		Review Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy Elina Zotova, James AR Nicoll, Raj Kalaria, Clive Holmes, Delphine Boche Alzheimer's Research & Therapy 2010, 2:1 (22 January 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Zotova et al. review the immune processes involved in Alzheimer’s disease pathogenesis and highlight the importance of addressing neuro-immune interactions when devising therapeutic strategies.
		Research Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease Susan D Rountree, Wenyaw Chan, Valory N Pavlik, Eveleen J Darby, Samina Siddiqui, Rachelle S Doody Alzheimer's Research & Therapy 2009, 1:7 (21 October 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Persistent treatment with cholinesterase inhibitors and/or memantine had a positive impact on Alzheimers disease (AD) progression by multiple cognitive and functional outcome measures.
		Review Proteinopathy-induced neuronal senescence: a hypothesis for brain failure in Alzheimer's and other neurodegenerative diseases Todd E Golde, Victor M Miller Alzheimer's Research & Therapy 2009, 1:5 (12 October 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Golde and Miller propose an integrative hypothesis that provides new insights into how a variety of misfolded protein aggregates can result in neurodegeneration.
		Review Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease Roy O Weller, Stephen D Preston, Malavika Subash, Roxana O Carare Alzheimer's Research & Therapy 2009, 1:6 (12 October 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Weller et al. highlight the importance of addressing neuro-immune interactions when devising therapeutic strategies for Alzheimer's disease.
		Review Angiotensins and Alzheimer's disease: a bench to bedside overview Patrick G Kehoe Alzheimer's Research & Therapy 2009, 1:3 (9 July 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Kehoe proposes angiotensins and associated enzymatic pathways as important mediators of recognized but undefined links between blood pressure and Alzheimer’s disease.
		Commentary Alzheimer's disease therapeutic research: the path forward Paul S Aisen Alzheimer's Research & Therapy 2009, 1:2 (9 July 2009) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Despite recent negative trial results, a clear path forward is emerging in Alzheimer’s disease therapeutic research using newly available tools to allow the study of new treatments at earlier stages in the disease process.
		Editorial Welcome to Alzheimer's Research & Therapy Ann Donnelly, Doug Galasko, Todd Golde, Frances Mulvany, Gordon Wilcock Alzheimer's Research & Therapy 2009, 1:1 (9 July 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Douglas Galasko, Todd Golde and Gordon Wilcock, Editors-in-chief, introduce Alzheimer’s Research & Therapy, the major forum for translational research into Alzheimer’s disease.
		Review Beyond mild cognitive impairment: vascular cognitive impairment, no dementia (VCIND) Blossom CM Stephan, Fiona E Matthews, Kay-Tee Khaw, Carole Dufouil, Carol Brayne Alzheimer's Research & Therapy 2009, 1:4 (9 July 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Stephan et al. review the concept of ‘vascular cognitive impairment, no dementia’ (VCIND) and its application for screening individuals at increased risk of dementia secondary to vascular disease and its risk factors.